study to compaire the role of Ayurvedic and modern medicine in CKD.

Comparative efficacy of Bruhatyadi Kwath as compare to furosemide for improving e-GFR and Albuminuria in Chronic Kidney Disease.

Status

Active, not recruiting

Phases

Phase 3

Study type

Observational

Source

CTRI

Registry ID

CTRI/2022/07/043780

Enrollment

Registered

2022-07-06

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.age 20years to 70 years. 2. diagnosed patient of CKD (BEST on eGFR,and Albuminuria clinically stable patient of stage 1to3 will be included stage 1- GFR >90. stage2- gfr between 60 to 89 stage 3-3a.eGFR 45TO 3b.eGFR 30 TO <45

Exclusion criteria

Exclusion criteria: 1.post renal transplant. 2. known case of HIV patients or subjects or subjects on immune suppressive drug. 3. pregnant and lactating femeles

Design outcomes

Primary

Measure	Time frame
1.To access the efficacy of bruhatyadi kwath on symptoms,e GFR,and Albuminuria in Chronic Kidney Disease. 2.To access the efficacy of bruhtyadi kwath with furosemide on symptomes, eGFR and albuminuria chronic Kidney disease. 3.To access the efficacy of furosemide on symptoms, eGFR And albuminuria in chronic kidney disease 4.To compare the effect of above therapy in various stages of chronic kidney disease.Timepoint: Assessment will be reported on baseline, 30th day, 60 th day,&90th day on the basis of subjective & objective parameters	—

Measure

Time frame

1.To access the efficacy of bruhatyadi kwath on symptoms,e GFR,and Albuminuria in Chronic Kidney Disease. 2.To access the efficacy of bruhtyadi kwath with furosemide on symptomes, eGFR and albuminuria chronic Kidney disease. 3.To access the efficacy of furosemide on symptoms, eGFR And albuminuria in chronic kidney disease 4.To compare the effect of above therapy in various stages of chronic kidney disease.Timepoint: Assessment will be reported on baseline, 30th day, 60 th day,&90th day on the basis of subjective & objective parameters

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Sadhana Misar

MGAC AND RC

sadhanamisar@gmail.com9763732083

Outcome results